Peregrine Pharmaceuticals (NASDAQ:PPHM) (NASDAQ:PPHMP) announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible …
In a research report issued today, MLV analyst Thomas Yip maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a price target of …
In a research report issued today, MLV analyst Thomas Yip reiterated a Buy rating on Peregrine Pharmaceuticals (NASDAQ:PPHM) with a $3.50 price target, after …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on oncology and the treatment of lung and breast cancers through the development of bavituximab, a …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology (I-O) agent in Phase III development for the treatment of lung …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of data from preclinical studies demonstrating the combination of phosphatidylserine (PS) blockade with anti-PD-1 or anti-CTLA-4 immune …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of data from clinical translational studies of the company’s phosphatidylserine (PS)-targeting immunotherapy bavituximab. Initial data from a …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting …
Peregrine Pharmaceuticals (NASDAQ:PPHM), announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the company's lead investigational immunotherapy bavituximab plus …
